1,086 IDEXX Laboratories, Inc. $IDXX Shares Sold by Verdence Capital Advisors LLC

Verdence Capital Advisors LLC trimmed its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 22.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,721 shares of the company’s stock after selling 1,086 shares during the period. Verdence Capital Advisors LLC’s holdings in IDEXX Laboratories were worth $1,943,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. J.Safra Asset Management Corp purchased a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at about $25,000. Elevation Wealth Partners LLC lifted its stake in shares of IDEXX Laboratories by 188.2% in the 2nd quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock worth $26,000 after purchasing an additional 32 shares during the period. Pension & Wealth Management Advisors Inc. bought a new position in shares of IDEXX Laboratories in the 3rd quarter worth approximately $29,000. Arlington Trust Co LLC lifted its stake in shares of IDEXX Laboratories by 46.3% in the 2nd quarter. Arlington Trust Co LLC now owns 60 shares of the company’s stock worth $32,000 after purchasing an additional 19 shares during the period. Finally, Pin Oak Investment Advisors Inc. purchased a new position in shares of IDEXX Laboratories in the second quarter worth approximately $49,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on IDXX. Citigroup boosted their target price on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research report on Wednesday, August 5th. Wall Street Zen cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. UBS Group decreased their price target on shares of IDEXX Laboratories from $670.00 to $627.00 and set a “neutral” rating on the stock in a research report on Tuesday. Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. Finally, KeyCorp initiated coverage on shares of IDEXX Laboratories in a research note on Monday, October 12th. They set a “sector weight” rating on the stock. Nine analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, IDEXX Laboratories has a consensus rating of “Moderate Buy” and an average target price of $727.69.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director Lawrence D. Kingsley sold 2,203 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the completion of the transaction, the director directly owned 9,568 shares in the company, valued at approximately $5,090,941.44. The trade was a 18.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.79% of the stock is currently owned by insiders.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $561.25 on Wednesday. The stock has a 50-day simple moving average of $533.69 and a two-hundred day simple moving average of $576.39. IDEXX Laboratories, Inc. has a 52-week low of $500.61 and a 52-week high of $769.98. The firm has a market capitalization of $44.22 billion, a PE ratio of 39.47 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, topping analysts’ consensus estimates of $3.94 by $0.33. The company had revenue of $1.22 billion during the quarter, compared to analysts’ expectations of $1.20 billion. During the same quarter in the previous year, the company earned $3.50 EPS. The business’s quarterly revenue was up 9.7% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Equities analysts forecast that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.